Plasma Fractionation Market Report
First published: 11 October 2024 | Last updated: 25 May 2026 | Report Code: plasma-fractionation
Plasma Fractionation Market — USD 29.1 billion in 2023, Growing to USD 54.99B by 2033 at 6.4% CAGR
This report provides an in-depth analysis of the Plasma Fractionation market, covering market size, trends, technology advancements, and forecasts from 2023 to 2033. It offers insights into regional dynamics, industry leaders, and market segmentation.
Key Takeaways
- Global market projected from $29.10 Billion in 2023 to $54.99 Billion in 2033 at a 6.4% CAGR, signalling sustained expansion over the 2023 to 2033 period.
- North America is largest regional market, while no single fastest-growing region is stated because regional CAGR differences remain within 0.15 percentage points.
- North America is the largest region, increasing from $9.75 Billion in 2023 to $18.43 Billion in 2033, reflecting notable regional scale.
- Europe moves from $7.32 Billion in 2023 to $13.83 Billion in 2033, indicating meaningful regional growth alongside Asia Pacific and others.
- Asia Pacific expands from $6.17 Billion in 2023 to $11.65 Billion in 2033, supported by rising healthcare demand and therapeutic adoption.
- Top industry players include Grifols, CSL Behring, Octapharma, and Kedrion Biopharma, which are central to competitive developments.
Plasma Fractionation Market Report — Executive Summary
North America remains largest market by forecast-period value, while no single fastest-growing region is stated because top regional growth rates are separated by less than 0.15 percentage points. This report offers a focused analysis of the plasma fractionation sector, tracking market value from $29.10 Billion in 2023 to $54.99 Billion by 2033 with a 6.4% CAGR during the 2023 to 2033 forecast period. Drivers include growing need for plasma-derived therapies, aging populations, and rising healthcare expenditure that support demand for immunoglobulins, albumin, and clotting factors. Technological improvements in separation and processing, plus investments by established firms such as Grifols, CSL Behring, Octapharma, and Kedrion Biopharma, shape capacity and product pipelines. The market is structured across source types, users, technologies, applications, and product types, with hospitals, blood banks, and pharmaceutical companies central to distribution and use. Regional dynamics vary: North America is the largest regional market, while other areas such as Europe and Asia Pacific show substantial absolute growth. The analysis integrates primary interviews, secondary data, and expert validation to present actionable insights for stakeholders and investors considering production, R&D, and distribution strategies.
Key Growth Drivers
- Rising prevalence of conditions requiring plasma-derived therapies drives demand for immunoglobulins, albumin, and clotting factors.
- Expanding healthcare spending and improved access to advanced treatments increase procurement by hospitals and pharmaceutical manufacturers.
- Technological advances in fractionation and processing enhance product yields and safety, supporting larger-scale manufacturing.
- Strategic investments and pipeline expansion by leading companies bolster capacity and market reach across regions.
| Metric | Value |
|---|---|
| Study Period | 2023 - 2033 |
| 2023 Market Size | $29.10 Billion |
| CAGR (2023-2033) | 6.4% |
| 2033 Market Size | $54.99 Billion |
| Top Companies | Grifols, CSL Behring, Octapharma, Kedrion Biopharma |
| Published Date | 11 October 2024 |
| Last Modified Date | 25 May 2026 |
Plasma Fractionation Market Overview
Customize Plasma Fractionation Market Report market research report
- ✔ Get in-depth analysis of Plasma Fractionation market size, growth, and forecasts.
- ✔ Understand Plasma Fractionation's regional dynamics and industry-specific trends.
- ✔ Identify potential applications, end-user demand, and growth segments in Plasma Fractionation
What is the Market Size & CAGR of Plasma Fractionation Market Report market in 2023?
Plasma Fractionation Industry Analysis
Plasma Fractionation Market Segmentation and Scope
Tell us your focus area and get a customized research report.
Plasma Fractionation Market Report Market Analysis Report by Region
Europe Plasma Fractionation Market Report:
Europe grows from $7.32 Billion in 2023 to $13.83 Billion in 2033. Regional expansion is driven by increasing therapeutic needs, regulatory frameworks supporting product quality, and adoption of improved fractionation technologies across clinical and manufacturing settings.Asia Pacific Plasma Fractionation Market Report:
Asia Pacific grows from $6.17 Billion in 2023 to $11.65 Billion in 2033. Growth reflects rising healthcare access, higher prevalence of conditions treated with plasma-derived products, and broader uptake of advanced processing methods in manufacturing hubs.North America Plasma Fractionation Market Report:
North America is largest regional market, rising from $9.75 Billion in 2023 to $18.43 Billion in 2033. 75 Billion in 2023 and is projected to reach $18.43 Billion by 2033. As the largest regional market, established healthcare infrastructure, significant demand for plasma-derived treatments, and investments by major firms contribute to continued scale and delivery capacity.South America Plasma Fractionation Market Report:
Latin America grows from $2.74 Billion in 2023 to $5.17 Billion in 2033. 74 Billion in 2023 and increases to $5.17 Billion by 2033, influenced by growing demand for plasma-derived therapies, developing healthcare systems, and enhanced distribution channels for critical care and specialty products.Middle East & Africa Plasma Fractionation Market Report:
Middle East and Africa grows from $3.12 Billion in 2023 to $5.9 Billion in 2033. Expansion is supported by increasing healthcare investment, rising demand for immunoglobulins and clotting factors, and gradual improvements in collection and processing infrastructure.Tell us your focus area and get a customized research report.
Research Methodology
Plasma Fractionation Market Analysis By Product Type
The market for plasma-derived products is predominantly composed of Human Plasma, projected to expand from $25.49 billion in 2023 to $48.16 billion by 2033, holding a market share of 87.58%. Animal Plasma is expected to grow from $3.61 billion to $6.83 billion in the same period, making up 12.42% of the market.
Plasma Fractionation Market Analysis By Application
In applications, immune deficiencies and hemophilia constitute major areas of focus, with human plasma treatments estimated at $13.46 billion and $6.36 billion respectively in 2023. These numbers are expected to rise to $25.43 billion and $12.03 billion by 2033.
Plasma Fractionation Market Analysis By End User
Hospitals are the largest end-user segment in the Plasma Fractionation market, forecasted to grow from $13.46 billion in 2023 to $25.43 billion by 2033. Clinics and blood banks will also see significant growth in their contributions to the market.
Plasma Fractionation Market Analysis By Source
The segmentation by source highlights a leading role of cold ethanol precipitation, expected to grow significantly due to its efficacy and cost-effectiveness. Ion exchange chromatography is also gaining traction, with planned innovations enhancing its application in the fractionation process.
Plasma Fractionation Market Analysis By Technology
Cold ethanol precipitation stands as the most adopted technology, holding a market share of 62.09% in 2023, while ion exchange chromatography follows with a notable presence. As technology evolves, integration of advanced filtration systems is expected to become more prevalent in the industry.
Plasma Fractionation Market Trends and Future Forecast
Tell us your focus area and get a customized research report.
Global Market Leaders and Top Companies in Plasma Fractionation Industry
Grifols:
Grifols is a global healthcare company and a leading producer of plasma-derived medicines, with a strong focus on innovation and expanding their pipeline of therapeutic products.CSL Behring:
CSL Behring specializes in lifesaving biotherapies, dedicated to high-quality standards in developing and manufacturing therapies derived from human plasma.Octapharma:
Octapharma is an international leader in the production of human proteins derived from human plasma, committed to enhancing the quality of life for patients worldwide.Kedrion Biopharma:
Kedrion Biopharma focuses on human plasma-derived therapies, continually investing in the development of innovative solutions for patient care.We're grateful to work with incredible clients.
FAQs
What is the market size of the plasma fractionation market in 2023?
The market size for plasma fractionation in 2023 is $29.10 Billion, as stated in the report, representing the baseline for the 2023 to 2033 forecast period referenced throughout the analysis.
How big will the market be by 2033?
By 2033 the market is projected to reach $54.99 Billion according to the provided forecast, reflecting growth over the 2023 to 2033 period driven by demand for plasma-derived therapies.
What is CAGR of the market for 2023 to 2033?
The compound annual growth rate for the 2023 to 2033 forecast period is 6.4%, as specified in the report, describing the average yearly expansion across the decade.
Is there a single fastest Growing region in the Plasma Fractionation Market Report market?
No single fastest-growing region is stated for the Plasma Fractionation Market Report market because the top regional implied CAGR values are within 0.15 percentage points of each other, making the ranking too close to call reliably.
Which companies are leading the plasma fractionation sector?
Top companies listed in the report include Grifols, CSL Behring, Octapharma, and Kedrion Biopharma, which influence production capacity, R&D priorities, and market dynamics.
What are common end users for fractionated plasma products?
End users noted include hospitals, clinics, blood banks, pharmaceutical companies, and research institutes, which source immunoglobulins, albumin, and clotting factors for clinical and research needs.
What technologies are applied in plasma fractionation?
Technologies outlined include cold ethanol precipitation, ion exchange chromatography, and filtration, which are used to separate and purify plasma-derived therapeutic components.
How big is the Europe market in 2023 and 2033?
Europe is reported at $7.32 Billion in 2023 and grows to $13.83 Billion by 2033, showing substantive regional expansion over the 2023 to 2033 forecast span.